Search Results

Peptomyc S.L. announces that it has received full study approval for its new Phase 1b clinical trial, which will evaluate the combination of the first-in-class MYC inhibitor, OMO103, together with the standard of care (SoC) regimen Gemcitabine and Nab-Paclitaxel in metastatic Pancreatic Ductal Adenocarcinoma (PDAC) patients in first line.

Co-founded back in 2014 by VHIO’s Laura Soucek, CEO of the enterprise, and Marie-Eve Beaulieu, Chief Scientific Officer (CSO) of the company, VHIO-born spin-off Peptomyc S.L . has just announced that it has received approval from the Spanish Agency of Medicines and Medical Devices for conducting clinical trials in Spain (AEMPS), to initiate the first-in-human Phase I/II clinical trial with its first compound

Peptomyc S.L., a biotech company specialized in the development of protein and peptide therapeutics targeting the Myc oncoprotein for cancer treatment, announces today that has appointed veteran pharma and biotech executive Giacomo Di Nepi as Chairman of the Board . Mr. Di Nepi has accumulated nearly 40 years of global experience in the Healthcare sector . His career started with 16 years at McKinsey & Company, where he was a Partne

Peptomyc, a Spanish clinical stage biotech company spin-off of the Vall d’Hebron Institute of Oncology and the Catalan Institute of Research and Advanced Studies in Barcelona, reported that on Tuesday 4th May the first patient has been dosed with OMO-103, its anti-MYC lead compound, in a Phase I/II study, under the supervision of Dr. Elena Garralda at the Hospital Universitari Vall d’Hebron in Barcelona.

The cell penetrating peptide market refers to the industry involved in the production, development, and commercialization of cell penetrating peptides (CPPs).

Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

The demand in the global ear infection treatment market is expected to increment at a healthy CAGR during the forecast period of 2020 to 2029, gaining traction from a number of factors such as rising percentage of geriatrics in the world population, the prevalence of target diseases, growing demand for early detection of incurable diseases, and the presentation of innovative applications.

Winner SunRegen Healthcare is focused on innovative treatments for patients with neurodegenerative eye diseases

Thomas de Vlaam, CEO and founder of Amylon Therapeutics, will receive a complimentary registration to BIO-Europe Spring 2018 from EBD Group and the opportunity to enter a year-long no fee arrangement to become a J&J Innovation, JLINX community member.